UroGen Pharma: An Emerging GARP Stock

Bret Jensen Investing Group Leader Follow Summary UroGen Pharma has pulled back 30% after a 208% rally, driven by Zusduri’s strong launch as the only approved non-surgical LG-IR-NMIBC therapy. Zusduri’s rapid uptake, favorable patient preference, and robust clinical data support continued growth, with patent protection until 2044 and 95% reimbursement coverage. URGN faces looming clinical competition but currently only contends with TURBT, positioning it for robust growth through at least 2027. With analysts projecting significant earnings growth and a $1B portfolio by 2030, the recent stock pullback offers an attractive entry point. An analysis around UroGen Pharma follow in the paragraphs below. Looking for a helping hand in the market? Members of The Biotech Forum get exclusive ideas and guidance to navigate any climate. Learn More » Getty Images Shares of bladder and urothelial cancer concern UroGen Pharma Ltd. ( URGN ) has retreated roughly 30% after a four-and-a-half-month 208% rally that was triggered by an encouraging launch of Zusduri. Driven by its RTGel delivery system that keeps medicine in This article was written by Bret Jensen 58.75K Followers Follow Bret Jensen has been investing since the 1980s. He has been writing for Real Money Pro and Seeking Alpha since 2010. Bret specializes in high beta sectors with potentially large investor returns.Bret leads the investing group The Biotech Forum, in which he and his team offer a model portfolio with their favorite 12-20 high upside biotech stocks, live chat to discuss trade ideas, and weekly research and option trades. The group also provides market commentary, and a portfolio update every weekend. Learn More. Analyst’s Disclosure: I/we have a beneficial long position in the shares of CGON,URGN either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.